PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 22, 2016Anesthesiology431 citations

Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery

View Full Paper
PRPavel S RoshanovBRBram RochwergAPAmeen Patel

Structured PICO

Does withholding angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers reduce death and postoperative vascular events in patients undergoing major noncardiac surgery?

P
Population
Patients undergoing major noncardiac surgery
I
Intervention
Withholding angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 24 hours before surgery
C
Comparator
Continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
O
Outcome
Death and postoperative vascular eventshard clinical

Withholding ACE inhibitors or ARBs 24 hours before major noncardiac surgery may reduce the risk of postoperative mortality and vascular events, though randomized trials are needed to confirm this practice.

Limitations

  • Lack of randomized trial data to confirm the finding

Abstract

Withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers before major noncardiac surgery was associated with a lower risk of death and postoperative vascular events. A large randomized trial is needed to confirm this finding. In the interim, clinicians should consider recommending that patients withhold angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers 24 h before surgery.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Roshanov et al. (2016) studied this question.

synapsesocial.com/papers/69d7c42005ee2ba81dbedc8ehttps://doi.org/10.1097/aln.0000000000001404
Ask AI
Helpful
Bookmark
Share
View Full Paper